Savoir Faire Capital Management L.P. Acquires 14,054 Shares of The Clorox Company (NYSE:CLX)

Savoir Faire Capital Management L.P. lifted its stake in The Clorox Company (NYSE:CLX - Free Report) by 253.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,602 shares of the company's stock after purchasing an additional 14,054 shares during the period. Clorox accounts for 2.5% of Savoir Faire Capital Management L.P.'s portfolio, making the stock its 14th largest position. Savoir Faire Capital Management L.P.'s holdings in Clorox were worth $2,886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Corient Private Wealth LLC boosted its position in shares of Clorox by 0.4% during the fourth quarter. Corient Private Wealth LLC now owns 28,652 shares of the company's stock worth $4,653,000 after buying an additional 117 shares during the period. Generali Asset Management SPA SGR bought a new position in shares of Clorox during the 4th quarter worth approximately $940,000. Vinva Investment Management Ltd raised its position in shares of Clorox by 147.7% in the fourth quarter. Vinva Investment Management Ltd now owns 6,627 shares of the company's stock valued at $1,070,000 after purchasing an additional 3,952 shares during the period. iA Global Asset Management Inc. acquired a new stake in Clorox during the fourth quarter worth approximately $2,768,000. Finally, Millstone Evans Group LLC acquired a new position in Clorox in the 4th quarter valued at $31,000. Institutional investors own 78.53% of the company's stock.

Analyst Upgrades and Downgrades

CLX has been the subject of several research reports. Barclays set a $119.00 price objective on shares of Clorox and gave the company an "underweight" rating in a research note on Tuesday, July 15th. Citigroup reissued a "neutral" rating and issued a $135.00 price target (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. UBS Group decreased their price objective on Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a report on Thursday. JPMorgan Chase & Co. cut their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Finally, Evercore ISI set a $140.00 price objective on shares of Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Clorox currently has an average rating of "Hold" and a consensus price target of $145.17.

Clorox Price Performance

CLX traded down $1.13 during trading on Monday, reaching $127.24. The stock had a trading volume of 667,255 shares, compared to its average volume of 1,426,442. The business has a 50-day moving average of $127.36 and a 200-day moving average of $141.06. The Clorox Company has a one year low of $117.35 and a one year high of $171.37. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The stock has a market cap of $15.68 billion, a PE ratio of 22.82, a PEG ratio of 3.37 and a beta of 0.51.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same period last year, the business posted $1.71 earnings per share. The company's revenue was down 8.0% compared to the same quarter last year. As a group, equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Pierre R. Breber purchased 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director directly owned 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is owned by corporate insiders.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.